VCYT — Veracyte, Inc.

Summary of Veracyte (VCYT) Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 Revenue: $141 million, a 19% year-over-year increase.
• Full Year Revenue: $517 million, achieving 16% growth.
• Testing Revenue: $135.8 million in Q4, up 21% year-over-year.
• Testing Volume: Approximately 48,000 tests in Q4, a 16% increase.
• Adjusted EBITDA Margin: 30.1% in Q4; full-year adjusted EBITDA margin was 27.6%, exceeding the 25% target.
• Net Income: GAAP net income of $41.1 million for Q4 and $66.4 million for the full year.
• Cash Position: Ended Q4 with $412.9 million in cash and cash equivalents.

2. Strategic Updates and Business Highlights

• Core Business Growth: Decipher testing volume grew 21% and Afirma by 12% in Q4, contributing to a total testing volume growth of 16%.
• Product Launches: Preparing for the launch of TrueMRD for muscle invasive bladder cancer and Prosigna for early-stage breast cancer in 2026.
• Operational Improvements: Transitioned Afirma to a more scalable v2 transcriptome platform, enhancing operational efficiency.
• Clinical Evidence: Continued generation of clinical data supporting Decipher and Afirma, with over 100 publications demonstrating Decipher's utility.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Total revenue expected between $570 million and $582 million, representing 10% to 13% growth.
• Testing Revenue Growth: Projected growth of 14% to 16% for testing revenue, with Afirma expected to grow in the mid- to high single digits and Decipher around 20%.
• Adjusted EBITDA Margin: Expected to be approximately 25% in 2026, with Q1 anticipated to be lower due to seasonality.

4. Bad News, Challenges, or Points of Concern

• Seasonality Impact: Q1 typically sees lower volume for Afirma and potential weather impacts on Decipher volume.
• Competitive Pressures: While Decipher has strong growth, competitors are also investing heavily, which could impact market share.
• Investment Needs: The need for significant investment in new product launches and clinical evidence generation may pressure margins in the short term.

5. Notable Q&A Insights

• Guidance Confidence: Management expressed strong conviction in their 2026 guidance, citing factors like no result rates and prior period collections as potential drivers for exceeding expectations.
• Decipher Market Dynamics: Decipher's growth remains strong despite competition, with management noting that approximately 67% of patients are still not utilizing the test.
• MRD Launch Strategy: The TrueMRD platform is expected to leverage existing relationships in urology, with a focus on clinical evidence and customer engagement ahead of its launch.
• Tax Rate Expectations: Anticipated mid-single-digit tax rate in 2026, with some state taxes expected as NOLs are depleted.

This summary encapsulates the key points from Veracyte's Q4 2025 earnings call, highlighting financial performance, strategic initiatives, future outlook, and potential challenges.